Percutaneous cryoablation of extraabdominal desmoid tumors: A 10-year experience

John J. Schmitz, Grant D. Schmit, Thomas D. Atwell, Matthew R Callstrom, Anil N. Kurup, Adam J. Weisbrod, Jonathan M. Morris

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

OBJECTIVE. Extraabdominal desmoid (EAD) tumors pose a therapeutic challenge because they often recur locally and behave aggressively. Accepted management options include surgery, radiation, chemotherapy, and observation. The objective of this study was to assess the safety and efficacy of percutaneous cryoablation for the treatment of EAD tumors. MATERIALS AND METHODS. A retrospective search of our cryoablation database was performed to identify patients with EAD tumors treated with percutaneous cryoablation between June 15, 2004, and June 15, 2014. During this 10-year time period, we treated 18 patients with 26 discrete tumors during 31 treatment sessions. After cryoablation, contrast-enhanced MRI or CT was performed. Any enhancing soft tissue was considered viable EAD tumor and was measured in three planes. RESULTS. Of the 26 EAD tumors treated, follow-up imaging with IV contrast material was available for 23 tumors. The mean imaging follow-up was 16.2 ± 20.0 (SD) months. All 31 sessions were technically successful procedures. No residual viable EAD tumor was observed in nine of 23 tumors (39.1%). Some degree of volume reduction was evident in 22 of 23 tumors (95.7%). Progressive disease was observed in one of the 23 tumors (4.3%). Of the cases with residual or progressive disease, the recurrence occurred at the margin of the treated tumor in all cases. No major complications were observed, and none of the complications was more severe than Clavien-Dindo grade I. CONCLUSION. Percutaneous cryoablation is a safe, effective, and repeatable treatment for achieving local control of EAD tumors.

Original languageEnglish (US)
Pages (from-to)190-195
Number of pages6
JournalAmerican Journal of Roentgenology
Volume207
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Aggressive Fibromatosis
Cryosurgery
antineoplaston A10
Neoplasms
Therapeutics
Contrast Media

Keywords

  • Aggressive fibromatosis
  • Cryoablation
  • Cryotherapy
  • Extraabdominal desmoid tumor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Schmitz, J. J., Schmit, G. D., Atwell, T. D., Callstrom, M. R., Kurup, A. N., Weisbrod, A. J., & Morris, J. M. (2016). Percutaneous cryoablation of extraabdominal desmoid tumors: A 10-year experience. American Journal of Roentgenology, 207(1), 190-195. https://doi.org/10.2214/AJR.15.14391

Percutaneous cryoablation of extraabdominal desmoid tumors : A 10-year experience. / Schmitz, John J.; Schmit, Grant D.; Atwell, Thomas D.; Callstrom, Matthew R; Kurup, Anil N.; Weisbrod, Adam J.; Morris, Jonathan M.

In: American Journal of Roentgenology, Vol. 207, No. 1, 01.07.2016, p. 190-195.

Research output: Contribution to journalArticle

Schmitz, JJ, Schmit, GD, Atwell, TD, Callstrom, MR, Kurup, AN, Weisbrod, AJ & Morris, JM 2016, 'Percutaneous cryoablation of extraabdominal desmoid tumors: A 10-year experience', American Journal of Roentgenology, vol. 207, no. 1, pp. 190-195. https://doi.org/10.2214/AJR.15.14391
Schmitz, John J. ; Schmit, Grant D. ; Atwell, Thomas D. ; Callstrom, Matthew R ; Kurup, Anil N. ; Weisbrod, Adam J. ; Morris, Jonathan M. / Percutaneous cryoablation of extraabdominal desmoid tumors : A 10-year experience. In: American Journal of Roentgenology. 2016 ; Vol. 207, No. 1. pp. 190-195.
@article{982f4ade15684a47b40f1e25cd147949,
title = "Percutaneous cryoablation of extraabdominal desmoid tumors: A 10-year experience",
abstract = "OBJECTIVE. Extraabdominal desmoid (EAD) tumors pose a therapeutic challenge because they often recur locally and behave aggressively. Accepted management options include surgery, radiation, chemotherapy, and observation. The objective of this study was to assess the safety and efficacy of percutaneous cryoablation for the treatment of EAD tumors. MATERIALS AND METHODS. A retrospective search of our cryoablation database was performed to identify patients with EAD tumors treated with percutaneous cryoablation between June 15, 2004, and June 15, 2014. During this 10-year time period, we treated 18 patients with 26 discrete tumors during 31 treatment sessions. After cryoablation, contrast-enhanced MRI or CT was performed. Any enhancing soft tissue was considered viable EAD tumor and was measured in three planes. RESULTS. Of the 26 EAD tumors treated, follow-up imaging with IV contrast material was available for 23 tumors. The mean imaging follow-up was 16.2 ± 20.0 (SD) months. All 31 sessions were technically successful procedures. No residual viable EAD tumor was observed in nine of 23 tumors (39.1{\%}). Some degree of volume reduction was evident in 22 of 23 tumors (95.7{\%}). Progressive disease was observed in one of the 23 tumors (4.3{\%}). Of the cases with residual or progressive disease, the recurrence occurred at the margin of the treated tumor in all cases. No major complications were observed, and none of the complications was more severe than Clavien-Dindo grade I. CONCLUSION. Percutaneous cryoablation is a safe, effective, and repeatable treatment for achieving local control of EAD tumors.",
keywords = "Aggressive fibromatosis, Cryoablation, Cryotherapy, Extraabdominal desmoid tumor",
author = "Schmitz, {John J.} and Schmit, {Grant D.} and Atwell, {Thomas D.} and Callstrom, {Matthew R} and Kurup, {Anil N.} and Weisbrod, {Adam J.} and Morris, {Jonathan M.}",
year = "2016",
month = "7",
day = "1",
doi = "10.2214/AJR.15.14391",
language = "English (US)",
volume = "207",
pages = "190--195",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "1",

}

TY - JOUR

T1 - Percutaneous cryoablation of extraabdominal desmoid tumors

T2 - A 10-year experience

AU - Schmitz, John J.

AU - Schmit, Grant D.

AU - Atwell, Thomas D.

AU - Callstrom, Matthew R

AU - Kurup, Anil N.

AU - Weisbrod, Adam J.

AU - Morris, Jonathan M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - OBJECTIVE. Extraabdominal desmoid (EAD) tumors pose a therapeutic challenge because they often recur locally and behave aggressively. Accepted management options include surgery, radiation, chemotherapy, and observation. The objective of this study was to assess the safety and efficacy of percutaneous cryoablation for the treatment of EAD tumors. MATERIALS AND METHODS. A retrospective search of our cryoablation database was performed to identify patients with EAD tumors treated with percutaneous cryoablation between June 15, 2004, and June 15, 2014. During this 10-year time period, we treated 18 patients with 26 discrete tumors during 31 treatment sessions. After cryoablation, contrast-enhanced MRI or CT was performed. Any enhancing soft tissue was considered viable EAD tumor and was measured in three planes. RESULTS. Of the 26 EAD tumors treated, follow-up imaging with IV contrast material was available for 23 tumors. The mean imaging follow-up was 16.2 ± 20.0 (SD) months. All 31 sessions were technically successful procedures. No residual viable EAD tumor was observed in nine of 23 tumors (39.1%). Some degree of volume reduction was evident in 22 of 23 tumors (95.7%). Progressive disease was observed in one of the 23 tumors (4.3%). Of the cases with residual or progressive disease, the recurrence occurred at the margin of the treated tumor in all cases. No major complications were observed, and none of the complications was more severe than Clavien-Dindo grade I. CONCLUSION. Percutaneous cryoablation is a safe, effective, and repeatable treatment for achieving local control of EAD tumors.

AB - OBJECTIVE. Extraabdominal desmoid (EAD) tumors pose a therapeutic challenge because they often recur locally and behave aggressively. Accepted management options include surgery, radiation, chemotherapy, and observation. The objective of this study was to assess the safety and efficacy of percutaneous cryoablation for the treatment of EAD tumors. MATERIALS AND METHODS. A retrospective search of our cryoablation database was performed to identify patients with EAD tumors treated with percutaneous cryoablation between June 15, 2004, and June 15, 2014. During this 10-year time period, we treated 18 patients with 26 discrete tumors during 31 treatment sessions. After cryoablation, contrast-enhanced MRI or CT was performed. Any enhancing soft tissue was considered viable EAD tumor and was measured in three planes. RESULTS. Of the 26 EAD tumors treated, follow-up imaging with IV contrast material was available for 23 tumors. The mean imaging follow-up was 16.2 ± 20.0 (SD) months. All 31 sessions were technically successful procedures. No residual viable EAD tumor was observed in nine of 23 tumors (39.1%). Some degree of volume reduction was evident in 22 of 23 tumors (95.7%). Progressive disease was observed in one of the 23 tumors (4.3%). Of the cases with residual or progressive disease, the recurrence occurred at the margin of the treated tumor in all cases. No major complications were observed, and none of the complications was more severe than Clavien-Dindo grade I. CONCLUSION. Percutaneous cryoablation is a safe, effective, and repeatable treatment for achieving local control of EAD tumors.

KW - Aggressive fibromatosis

KW - Cryoablation

KW - Cryotherapy

KW - Extraabdominal desmoid tumor

UR - http://www.scopus.com/inward/record.url?scp=84979021941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979021941&partnerID=8YFLogxK

U2 - 10.2214/AJR.15.14391

DO - 10.2214/AJR.15.14391

M3 - Article

C2 - 27064168

AN - SCOPUS:84979021941

VL - 207

SP - 190

EP - 195

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 1

ER -